Results for extramedullary translation from English to Danish

extramedullary
extramedullær

extramedullary blood formation
extramedullær hæmopoiese

extramedullary haematopoiesis and splenic enlargement. pr
ekstramedullær hæmatopoiese og forstørrelse af milten. kk ri

no evidence of circulating blasts or extramedullary disease
ingen tegn på blaster i kredsløb eller ekstramedullær sygdom

extramedullary haematopoiesis in the spleen was observed in rats.
der blev observeret ekstramedullær hæmatopoiese i milten hos rotter.

these changes were associated with increased splenic extramedullary haematopoiesis, thymic atrophy and decreased hepatic haematopoiesis.
disse ændringer var associeret med forøget ekstramedullær hæmatopoiese i milten, thymus atrofi og nedsat hepatisk hæmatopoiese.

blast crisis is defined as blasts 30% in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
blastkrise defineres som 30% blaster i blod eller knoglemarv eller ekstramedullær sygdom ud over hepatosplenomegali.

blast crisis is defined as blasts ≥ 30 % in blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
blastkrise defineres som 30 % blaster i blod eller knoglemarv eller ekstramedullær sygdom ud over hepatosplenomegali.

due to its lack of extramedullary toxicity despite dose escalation beyond myelotoxic doses, thiotepa has been used for decades in combination with other chemotherapy medicinal products prior to autologous and allogeneic hpct.
som følge af dets mangel på ekstramedullær toksicitet trods dosisoptrapning ud over myelotoksiske doser er thiotepa blevet anvendt i årtier i kombination med andre kemoterapeutika før autolog og allogen hpct.

preclinical data from conventional studies of repeated dose toxicity revealed the expected pharmacological effects including increases in leukocyte count, myeloid hyperplasia in bone marrow, extramedullary haematopoiesis and splenic enlargement.
prækliniske data fra konventionelle studier med gentaget dosistoksicitet viste de forventede farmakologiske effekter inklusiv stigning i leukocyttallet, myeloid hyperplasi i knoglemarven, ekstramedullær hæmatopoiese og forstørrelse af milten.

filgrastim was studied in repeated dose toxicity studies up to 1 year in duration which revealed changes attributable to the expected pharmacological actions including increases in leukocytes, myeloid hyperplasia in bone marrow, extramedullary granulopoiesis and splenic enlargement.
filgrastim blev undersøgt i studier af toksiciteten efter gentagne doser af op til 1 års varighed, hvor der blev observeret ændringer, som kunne tilskrives de forventede farmakologiske virkninger, herunder stigninger i leukocytter, myeloid hyperplasi i knoglemarv, ekstramedullær granulopoiese og forstørret milt.

wbc ≤ institutional uln, anc ≥ 1000/ mm3, platelets ≥ 100,000/ mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤ 5%, < 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood < 20%, and no extramedullary involvement.
wbc ≤ institutionens uln, anc ≥ 1. 000/ mm3, trombocytter ≥ 100. 000/ mm3, ingen blaster eller promyelocytter i perifert blod, knoglemarvsblaster ≤ 5%, < 5% myelocytter plus metamyelocytter i perifert blod, basofilocytter i perifert blod < 20% og ingen ekstramedullær involvering.